Compare BEEP & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BEEP | CRDL |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.2M | 97.3M |
| IPO Year | 2021 | 2017 |
| Metric | BEEP | CRDL |
|---|---|---|
| Price | $3.06 | $1.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $6.75 | ★ $9.00 |
| AVG Volume (30 Days) | 42.9K | ★ 348.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 90.20 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $37,008,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.97 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 22.25 | N/A |
| 52 Week Low | $2.50 | $0.77 |
| 52 Week High | $4.67 | $1.59 |
| Indicator | BEEP | CRDL |
|---|---|---|
| Relative Strength Index (RSI) | 51.20 | 51.63 |
| Support Level | $3.04 | $1.03 |
| Resistance Level | $3.25 | $1.09 |
| Average True Range (ATR) | 0.20 | 0.06 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 52.29 | 41.62 |
Mobile Infrastructure Corp focuses on acquiring, owning, and leasing parking facilities and related infrastructure, including parking lots, parking garages and other parking structures throughout the United States. It operates in a single reportable segment: parking. The parking segment derives revenue from managed property revenue and rental income at parking facilities. The company provide access to property and space for the parker's vehicle and charges fees that vary based on the level of usage. The company derives all of its revenue domestically.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.